Satori Neuro

Satori Neuro is a thematic investment strategy operating under Satori Capital, a multi-strategy investment firm. It is dedicated to investing in transformational companies that are pioneering breakthroughs in brain and mental health, with a broader aim to drive transformative impact on human well-being. The firm focuses on innovative solutions, including therapeutics, neurotechnology, and disruptive business models, to address critical mental health challenges and foster human flourishing.

Satori Capital, the parent firm, was founded in 2008 by Randy Eisenman and Sunny Vanderbeck, built upon the principles of conscious capitalism. Satori Neuro was officially launched in February 2023, specifically to pursue opportunities within the rapidly evolving mental health and neurotechnology sectors. This launch aligned with Satori Capital's overarching purpose to create, fund, and inspire businesses that elevate humanity.

While Satori Capital has a diverse portfolio, Satori Neuro's specific investments include companies like Feel Therapeutics, Motif Neurotech, Beckley Waves, TARA Mind, Apollo Neuro, Kindly Human, and Holobiome. These investments span areas such as therapeutic devices and drug discovery, reflecting a broad approach to mental and brain health solutions. Satori Neuro is a stage-agnostic fund, indicating investments across various growth stages from early seed rounds to later-stage growth equity.

The Satori Neuro strategy is led by Dr. Amy Kruse, Chief Investment Officer, who brings over two decades of extensive experience as a neuroscientist, operator, and government program manager. Her background includes roles at DARPA, Optios, Cubic Global Defense, and Prime Movers Lab, where she focused on neurotechnology and human performance. Dr. Kruse leverages her deep scientific expertise and robust network to identify promising companies and provide strategic support to Satori Neuro's portfolio, particularly in deploying complex technologies in real-world environments.